Content continues after advertisement

Research Note: Ki67 as Prognostic Factor inDogs with B-Cell Lymphoma


|June 2018

Sign in to Print/View PDF

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in dogs and humans. DLBCL has an aggressive and heterogeneous biologic course. Ki67 is an important marker of cell proliferation in humans with DLBCL. Mitotic index (MI) is another important indicator. Lymph node samples (n = 29) from dogs with DLBCL treated with a 19-week CHOP protocol were evaluated for Ki67 immunostaining and MI values. This study showed that Ki67 immunostaining on biopsy specimens was associated with shorter survival times in dogs with DLBCL. MI was not a prognostic factor, according to this study.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Continuing Education

Welcome to your new CE platform

Get started here.

With RACE-approved courses for the brief, relevant Clinician’s Brief articles you love, we’re your home for online CE.
Earn Hours
Earn up to 39.5 hours of RACE-approved CE with Clinician’s Brief content.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2018 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Privacy Policy (Updated 05/08/2018) Terms of Use (Updated 05/08/2018)